Stock·NASDAQ·Healthcare
DexCom Inc. (DXCM)
- Market cap
- $31.06B
- P/E
- 32.67
- Dividend yield
- None
- Street target
- $95.00median of 29 analysts
- 52-week range
- $54.11 $92.59
DXCM stock forecast today
Where DXCM stands today, and what CleaRank Financial AI makes of it.
DXCM at a glance
DexCom Inc. (DXCM): Buy, 67/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($74.56 and $85.82).
- Earnings DXCM beat estimates in 5 of its last 7 quarters, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $16.3M and bought $1.0M over the last 18 months.
- Valuation P/E of 32.7 against 31.9 for the Healthcare sector: broadly in line with peers (+2%).
Figures as of October 30, 2026.
CleaRank Financial AI
DexCom Inc. (DXCM) earns a CleaRank rating of Buy and a model score of 67/100.
Trend does the most to lift that score, with the price 10.41% above its 200-day average and the 50-day average 15.10% above the 200-day. Momentum pulls the score down the most, since the MACD line is negative. The 50-day average is $85.82 and the 200-day is $74.56, and over the past year the price has risen 20.70%.
Only on CleaRank
Figures we compute ourselves from DXCM's own price, earnings and insider-filing history. Tap one to see it in context.
DXCM stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price below its 50-day average ›
The price of $82.32 is 4.1% below the 50-day simple moving average of $85.82.Price above its 200-day average ›
The price is 10.4% above the 200-day simple moving average of $74.56.50-day average above the 200-day ›
The 50-day average ($85.82) is 15.1% above the 200-day average ($74.56), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 73% of its 52-week range, between $54.11 and $92.59.
DXCM share price
Pick a period: each tab shows how far DXCM has moved over it, to the last close.
Today's trading
Where DXCM sits inside today's range and its 52-week range.
DXCM fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/E above the sector median ›
The trailing P/E of 32.67 is 2.4% above the Healthcare median of 31.9.P/S above the sector median ›
The price-to-sales ratio of 6.25 is 83.9% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $999.7M on revenue of $5.0B, a net margin of 20.1%.Beat estimates in most recent reports ›
DXCM beat the EPS estimate in 5 of its last 7 reports.
Key statistics
The headline figures for DXCM.
As of October 30, 2026, DXCM trades at $82.32, with a market value of $31.06B and a P/E ratio of 32.67.
What the numbers say
CleaRank Financial AI's reading of DXCM's valuation, growth and risks.
DexCom Inc. (DXCM) trades on a trailing P/E of 32.67, which is 2.4% above the Healthcare median of 31.9. The peer comparison on this page rates that multiple as broadly in line with peers. Against sales, the price-to-sales ratio of 6.25 is 83.8% above the sector median of 3.4. To put the company in scale, its market capitalisation is $31.1B.
DXCM is outgrowing its sector: year on year, revenue expanded 13.10% in the latest quarter, compared with a sector median of 8.1%. Its net margin of 20.12% and operating margin of 24.33% show how much of each sale becomes profit. Return on equity of 38.49% sits above the sector median of 7.3%. On the balance sheet, debt-to-equity stands at 0.53.
DXCM's most recent earnings report, released on July 30, 2026, topped the estimate by 14.75%. The company posted $0.70 per share against a $0.61 forecast. The stock climbed 11.95% in the next session.
The earnings record shows 5 beats in 7 reports, though the stock still fell in the first session after 2 of those 5 beats. The October 30, 2025 report stands out among the few before the latest: a beat of 7.02%, after which the stock fell 14.63%. The consensus EPS estimate stands at $2.66 for this fiscal year and $3.12 for next, growth of 27.4% for the current year.
DXCM's typical daily move is about 2.06%, and its beta against the S&P 500 is 1.48. Over the last 18 months insiders unloaded $16.3M of shares while buying $1.0M on the open market. Insider sales are often planned ahead or made to cover taxes on vesting shares, so they carry less weight than purchases would.
DXCM against the Healthcare sector
How DXCM compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (2% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 20, 2025, DXCM has lost 5.8% against a gain of 37.3% for XLV.
Performance against XLV
DXCM and the Healthcare sector fund over the same days.
Revenue and earnings
How much DXCM sells, and how much of it becomes profit.
Revenue growth: Revenue grew 15.6% in FY2025 to $4.7B, from $4.0B a year earlier.
Profit margin: The net margin was 17.9% in FY2025, up from 14.3% the year before.
Profitable: DXCM earned $836M in FY2025.
Earnings reality check
Did DXCM beat what analysts expected, and how did the stock react?
Earnings record: DXCM beat the analyst estimate in 5 of the last 7 quarters.
Market reaction: The stock fell in the first session after 2 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 30, 2026after close | $0.61 | $0.70 | +14.75% | +11.95% | +11.38% |
| Apr 30, 2026after close | $0.47 | $0.56 | +19.15% | +3.02% | +2.28% |
| Feb 12, 2026after close | $0.65 | $0.68 | +4.62% | +7.59% | +12.29% |
| Oct 30, 2025after close | $0.57 | $0.61 | +7.02% | -14.63% | -14.93% |
| Jul 30, 2025after close | $0.44 | $0.48 | +9.09% | -9.31% | -14.22% |
| May 1, 2025after close | $0.33 | $0.32 | -3.03% | +16.17% | +21.46% |
| Feb 13, 2025after close | $0.50 | $0.45 | -10.00% | +5.92% | +5.58% |
As of October 30, 2026, DXCM has beaten the analyst EPS estimate in 5 of its last 7 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on July 30, 2026, came in 14.75% above the estimate and the stock moved +11.95% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
DXCM AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 47.8, in neutral territory.RSI below 50 ›
An RSI of 47.8 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line below zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank Financial AI analysis of DXCM
The score, the reasoning behind it, and what could move the price next.
DXCM is giving a mixed trend reading. At $82.32 the stock sits 4.08% below its 50-day average of $85.82, yet it is 10.41% above its 200-day average of $74.56. Within its 52-week range the price is near the top: it is 11.09% below the high of $92.59 and 52.13% above the low of $54.11. The 50-day average is 15.10% above the 200-day, so the longer averages have not yet caught up with the softer recent price.
A recent pullback sits inside a stronger longer record: the price fell 4.60% over the past month, fell 1.35% over the past three months and rose 20.70% over the past year. Volume in the last session ran 128.2% above its average, on a day the price rose 2.99%. The 14-day RSI of 47.8 is in the neutral zone, and the MACD line is negative.
Earnings beat ›
The July 30, 2026 report beat the EPS estimate by 14.75%, and the share price rose 11.95% in the first session after it.
Source: Earnings report, July 30, 2026New analyst coverage ›
Barclays started coverage at Overweight on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026Rating reaffirmed ›
BTIG kept its Buy rating on October 12, 2026.
Source: Analyst action, BTIG, October 12, 2026
- Keep an eye on the two closest levels: the 50-day SMA at $85.82 sits above the price, and the 200-day SMA at $74.56 sits below it.
- A 14-day RSI of 47.8 is in the neutral zone, and the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum.
- After the July 30, 2026 report the share price rose 11.95% in the first session; DXCM beat estimates in 5 of the last 7 reports.
DXCM is right at its 20-day EMA, so the short-term average gives no clear lean. The wider trend is mixed. The price is above the 200-day average of $74.56 but under the 50-day average of $85.82. Closing above the 50-day would bring both signals to the upside, while closing below the 200-day would bring both to the downside. Going down, the first support is the 200-day SMA at $74.56, and going up, the first resistance is the 50-day SMA at $85.82.
A 14-day RSI of 47.8 places DXCM in neutral territory, somewhere between 40 and 60.
Technical indicators
Momentum and trend for DXCM, from its daily closes.
As of October 30, 2026, with DXCM at $82.32, its 14-day RSI is 47.8 (neutral territory), its 50-day simple moving average is $85.82 and its 200-day is $74.56.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What DXCM moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, DXCM's 1-year correlation of daily returns is +0.34 with S&P 500 (SPY), +0.28 with Nasdaq 100 (QQQ), +0.06 with Bitcoin (BTC) and +0.03 with gold (XAU).
DXCM price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
26 of 29 analysts rate it a buy or strong buy, 3 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $95.00 is 15.4% above the price.More buy ratings than three months ago ›
26 of 29 rate it a buy now, against 25 of 28 three months ago.
DXCM Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 12, 2026 | BTIG | Maintains | Buy |
| Oct 7, 2026 | Barclays | Initiates | Overweight |
| Oct 1, 2026 | RBC Capital | Maintains | Outperform |
| Sep 18, 2026 | Truist Securities | Maintains | Buy |
| Sep 18, 2026 | TD Cowen | Reiterates | Buy |
| Aug 4, 2026 | Argus Research | Maintains | Buy |
As of October 30, 2026, 29 Wall Street analysts cover DXCM: 26 rate it a buy or strong buy, 3 a hold and 0 a sell or strong sell. Their 12-month price targets range from $79.00 to $115.00. The median DXCM price target is $95.00, 15.4% above the price of $82.32.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
DXCM trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
DXCM trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from DXCM's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much DXCM tends to move, against the market and on its own.
DXCM price history and drawdowns
DXCM's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move of 2% or more ›
The price has moved 2.06% on an average day (30-day standard deviation of daily returns).Not yet recovered from its worst fall ›
The worst fall was 66.1%, from November 2021 to November 2025; the price is still 49.2% below that peak.Most 1-year holds ended higher ›
61% of 1-year holding periods in the last 10 years ended with a gain.Trailed the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $40,864, against $42,358 in the S&P 500 (SPY).
DXCM Drawdowns & Recovery
As of October 30, 2026, DXCM's worst peak-to-trough fall over the last 10 years with dividends reinvested was -66.1% (November 2021 to November 2025); it is still 49.2% below that peak, and 61% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into DXCM in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: DXCM trailed the S&P 500 over this period: $40,864 against $42,358.
A $10,000 investment in DXCM in October 2016 would be worth about $40,864 today with dividends reinvested, compared with about $42,358 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to DXCM, and which have not.
Strongest month, November: an average of +7.66%, up in 6 of 10 years.
Weakest month, September: an average of -8.79%, up in 2 of 10 years.
This month, October: has averaged +3.41%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, DXCM's strongest calendar month has been November (average +7.66%, up in 6 of 10 years) and its weakest September (average -8.79%, up in 2 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
DXCM stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in DXCM, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in DXCM today could grow to about $14,252 by 2030 in the base case, with a 90th-percentile outcome near $51,184 and a 10th-percentile outcome around $3,968. Projections are statistical simulations, not guarantees.
DXCM Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $117 for DXCM by 2030 in the base case, from $82.32 today (1.4x over 4 years). The 10th-percentile path ends near $32.67. These are outcomes of a Monte Carlo simulation run on DXCM's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $47.46 | $89.94 | $170 | |
| 2028 | $39.79 | $98.27 | $243 | |
| 2029 | $35.48 | $107 | $325 | |
| 2030 | $32.67 | $117 | $421 |
Method: a lognormal simulation of DXCM's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. DXCM is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. How the simulation works
DXCM insider trading
What the people running the company have bought and sold.
DXCM insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $1.0M on the open market and sold $16.3M.
As of October 30, 2026, DXCM insiders reported 39 open-market sales worth $16.3M and 1 open-market purchase worth $1.0M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 15, 2026 | Michael Jon Brown
Officer
|
Sell | 1.7K | $145.3K |
| Sep 28, 2026 | Sadie Stern
Officer
|
Sell | 2.6K | $221.0K |
| Sep 15, 2026 | Nicholas Augustinos
Director
|
Sell | 8.1K | $679.8K |
| Sep 15, 2026 | Michael Jon Brown
Officer
|
Sell | 1.7K | $142.9K |
| Sep 10, 2026 | Jereme M Sylvain
Chief Financial Officer
|
Sell | 3.6K | $302.9K |
| Sep 10, 2026 | Glenn S Boehnlein
Director
|
Grant | 5.8K | - |
| Aug 27, 2026 | Sadie Stern
Officer
|
Sell | 2.6K | $226.7K |
| Aug 20, 2026 | Kevin R Sayer
Officer and Director
|
Sell | 26.8K | $2.4M |
| Aug 14, 2026 | Michael Jon Brown
Officer
|
Sell | 1.7K | $156.3K |
| Aug 12, 2026 | Bridgette P Heller
Director
|
Sell | 1.0K | $89.3K |
| Aug 12, 2026 | Nicholas Augustinos
Director
|
Grant | 1.1K | - |
| Aug 3, 2026 | Mark G Foletta
Director
|
Sell | 4.0K | $330.6K |
| Jul 20, 2026 | Kevin R Sayer
Officer and Director
|
Sell | 26.8K | $2.0M |
| Jul 15, 2026 | Michael Jon Brown
Officer
|
Sell | 1.7K | $126.5K |
| Jul 6, 2026 | Kevin R Sayer
Officer and Director
|
Sell | 26.8K | $1.9M |
| Jun 15, 2026 | Mark G Foletta
Director
|
Sell | 4.0K | $296.5K |
| Jun 15, 2026 | Michael Jon Brown
Officer
|
Sell | 1.7K | $128.4K |
| Jun 4, 2026 | Jon Coleman
Officer
|
Sell | 9.8K | $722.6K |
| May 28, 2026 | Steven R Altman
Director
|
Grant | 5.6K | - |
| May 28, 2026 | Euan A. Ashley
Director
|
Grant | 5.6K | - |
| May 28, 2026 | Nicholas Augustinos
Director
|
Grant | 5.6K | - |
| May 28, 2026 | Richard Alexander Collins
Director
|
Grant | 5.6K | - |
| May 28, 2026 | Rimma Driscoll
Director
|
Grant | 5.6K | - |
| May 28, 2026 | Mark G Foletta
Director
|
Grant | 6.3K | - |
| May 28, 2026 | Renee D Gala
Director
|
Grant | 5.6K | - |
| May 28, 2026 | Bridgette P Heller
Director
|
Grant | 5.6K | - |
| May 28, 2026 | Kyle Malady
Director
|
Grant | 5.6K | - |
| May 28, 2026 | Albert Frederick Osterloh IV
Director
|
Grant | 1.6K | - |
| May 21, 2026 | Kevin R Sayer
Officer and Director
|
Sell | 26.8K | $1.9M |
| May 15, 2026 | Michael Jon Brown
Officer
|
Sell | 1.7K | $101.8K |
| May 12, 2026 | Bridgette P Heller
Director
|
Sell | 1.0K | $60.7K |
| May 8, 2026 | Steven R Altman
Director
|
Grant | 5.0K | - |
| May 8, 2026 | Nicholas Augustinos
Director
|
Grant | 5.0K | - |
| May 8, 2026 | Richard Alexander Collins
Director
|
Grant | 5.1K | - |
| May 8, 2026 | Mark G Foletta
Director
|
Grant | 5.7K | - |
| Apr 15, 2026 | Michael Jon Brown
Officer
|
Sell | 1.7K | $107.2K |
| Mar 16, 2026 | Michael Jon Brown
Officer
|
Sell | 1.7K | $110.2K |
| Mar 6, 2026 | Michael Jon Brown
Officer
|
Grant | 39.0K | - |
| Mar 6, 2026 | Jon Coleman
Officer
|
Grant | 43.9K | - |
| Mar 6, 2026 | Jacob Steven Leach
Chief Executive Officer
|
Grant | 104.5K | - |
| Mar 6, 2026 | Kevin R Sayer
Officer and Director
|
Grant | 32.7K | - |
| Mar 6, 2026 | Sadie Stern
Officer
|
Grant | 39.0K | - |
| Mar 6, 2026 | Jereme M Sylvain
Chief Financial Officer
|
Grant | 48.8K | - |
| Feb 12, 2026 | Bridgette P Heller
Director
|
Sell | 1.0K | $68.8K |
| Jan 29, 2026 | Michael Jon Brown
Officer
|
Grant | 7.1K | - |
| Jan 29, 2026 | Jacob Steven Leach
Chief Executive Officer
|
Grant | 8.3K | - |
| Jan 29, 2026 | Kevin R Sayer
Officer and Director
|
Grant | 71.2K | - |
| Jan 29, 2026 | Sadie Stern
Officer
|
Grant | 7.1K | - |
| Jan 29, 2026 | Jereme M Sylvain
Chief Financial Officer
|
Grant | 7.1K | - |
| Nov 14, 2025 | Richard Alexander Collins
Director
|
Sell | 2.9K | $171.6K |
| Nov 12, 2025 | Bridgette P Heller
Director
|
Sell | 1.0K | $58.8K |
| Nov 10, 2025 | Richard Alexander Collins
Director
|
Sell | 3.9K | $217.8K |
| Nov 10, 2025 | Jacob Steven Leach
President
|
Buy | 18.2K | $1.0M |
| Oct 24, 2025 | Euan A. Ashley
Director
|
Grant | 7.2K | - |
| Sep 5, 2025 | Kyle Malady
Director
|
Sell | 667 | $53.9K |
| Sep 4, 2025 | Sadie Stern
Officer
|
Sell | 1.5K | $117.3K |
| Sep 2, 2025 | Jereme M Sylvain
Chief Financial Officer
|
Sell | 4.8K | $357.8K |
| Aug 15, 2025 | Mark G Foletta
Director
|
Sell | 2.8K | $222.9K |
| Aug 15, 2025 | Michael Jon Brown
Officer
|
Sell | 500 | $40.1K |
| Jul 28, 2025 | Sadie Stern
Officer
|
Sell | 1.5K | $130.5K |
| Jul 15, 2025 | Mark G Foletta
Director
|
Sell | 2.8K | $234.2K |
| Jul 15, 2025 | Michael Jon Brown
Officer
|
Sell | 500 | $43.0K |
| Jun 26, 2025 | Sadie Stern
Officer
|
Sell | 1.5K | $124.7K |
| Jun 16, 2025 | Nicholas Augustinos
Director
|
Sell | 6.3K | $517.9K |
| Jun 16, 2025 | Mark G Foletta
Director
|
Sell | 2.8K | $228.6K |
| Jun 16, 2025 | Michael Jon Brown
Officer
|
Sell | 500 | $41.4K |
| May 27, 2025 | Sadie Stern
Officer
|
Sell | 6.2K | $526.3K |
| May 23, 2025 | Michael Jon Brown
Officer
|
Sell | 10.0K | $842.8K |
| May 22, 2025 | Jon Coleman
Officer
|
Grant | 68.7K | - |
| May 8, 2025 | Steven R Altman
Director
|
Grant | 5.0K | - |
| May 8, 2025 | Steven R Altman
Director
|
Grant | 2.6K | - |
| May 8, 2025 | Nicholas Augustinos
Director
|
Grant | 5.0K | - |
| May 8, 2025 | Nicholas Augustinos
Director
|
Grant | 2.6K | - |
| May 8, 2025 | Richard Alexander Collins
Director
|
Grant | 5.1K | - |
| May 8, 2025 | Richard Alexander Collins
Director
|
Grant | 2.6K | - |
| May 8, 2025 | Karen M Dahut
Director
|
Grant | 2.6K | - |
| May 8, 2025 | Rimma Driscoll
Director
|
Grant | 5.1K | - |
| May 8, 2025 | Mark G Foletta
Director
|
Grant | 5.7K | - |
| May 8, 2025 | Mark G Foletta
Director
|
Grant | 3.0K | - |
| May 8, 2025 | Renee D Gala
Director
|
Grant | 5.1K | - |
| May 8, 2025 | Bridgette P Heller
Director
|
Grant | 5.0K | - |
| May 8, 2025 | Kyle Malady
Director
|
Grant | 5.2K | - |
| May 8, 2025 | Eric J Topol
Director
|
Grant | 2.6K | - |
Source: TwelveData, from SEC Form 4 filings
DXCM stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.